Replies to post #93235 on Rivulet Media Inc (fka RIVU)

[PG]

Beyond this are a host of drugs in pre-clinical or very early stage human studies at a variety of small biotechs. Assuming that no major safety issues appear in the late-stage trials of the anti-PD-1/PD-L1 approaches, it seems safe to assume that a wave of in-licensing and acquisitions will occur as Big Pharma players with weak immunotherapy portfolios look to strengthen their hand.

So while success with immunotherapy is certainly part of the bullish thesis for all three of these companies, it is only a part of a more complicated investment perspective.

Thank you!

BMSN

[sizzleweed]

That is HUGE, New. I am adding more shares tonight, I will BIATCH SLAP the ask. BMSN is such a bargain at this price, and that article confirmed what we know. We are on the eve of trial approval, any day, maybe tomorrow.

[sizzleweed]

Immunotherapy is just one new approach to fighting cancer, but it alone could ultimately encompass vaccines, oncolytic viruses, and adoptive t-cell technologies, creating a market of $25 billion to $40 billion by the end of the next decade.


That says it all for me. We are on the abyss of an inevitable change to fight cancer. And BMSN is a pioneer in this new-age technology. Welcome to the new age, Welcome to BMSN